CGT Industrial Upgrade Park Tour Series – Stop 11: Bayer Co.Lab Shanghai

Bayer Co.Lab, as Bayer’s co-creation platform for the global life sciences sector, is committed to providing startups with shared office spaces, advanced laboratory equipment, and personalized support services through its unique global network. Regarded as an ideal co-creation space for life science startups, Bayer Co.Lab enables resident companies to tap into Bayer’s global R&D network and expertise, connect with a worldwide innovation collaboration network, and leverage Bayer’s extensive internal and external expert resources to accelerate their innovation processes and business development. Currently, Bayer Co.Lab has established a strategic presence in multiple global innovation hubs, including the United States, Germany, China, and Japan.

In China, Bayer has partnered with the Shanghai Biomedical Frontier Industry Innovation Center to jointly establish Bayer Co.Lab, located in Shanghai Zhangjiang’s landmark open innovation park, which features world-class laboratory facilities and office spaces.Bayer Co.Lab officially opened on September 26, 2024, with plans to empower 8 to 10 local startups focused on cell and gene therapy (CGT), oncology, and new technology platforms. Bayer Co.Lab is currently actively conducting recruitment and is poised to welcome its first cohort of resident enterprises in China.

CoJourney is a professional gene and cell therapy CDMO integrating plasmid, viral vector, and mRNA manufacturing, preparation, and analytical testing. It has successful experience in submitting Investigational New Drug (IND) applications for plasmids and viral vectors in both China and the United States, achieving zero deficiency letters. CoJourney provides customized services including process development, cGMP manufacturing, analytical method development, and product release testing for plasmids, viral vectors, and mRNA.

Xingcheng Company was co-founded by senior CMC experts with commercialization experience in the field of gene and cell therapy, as well as accomplished scientists and entrepreneurs. With dual headquarters located in Zhejiang, China, and Pennsylvania, USA, the company has established GMP manufacturing facilities for plasmids, viral vectors, and mRNA that comply with FDA, EU, and NMPA regulations, equipped with advanced production and testing instruments. The team possessesWith extensive process development capabilities and hands-on experience, we uphold the philosophy of “Sincerity in Action.” By employing robust processes that exceed industry standards, we ensure the delivery of high-quality, cost-effective services characterized by high purity and high yield. Our offerings support partners across various production scales, from R&D to GMP-grade manufacturing of plasmids, viral vectors, and mRNA.

Yeasen Biotechnology (Shanghai) Co., Ltd. is a high-tech enterprise focused on core raw materials in the upstream life science industry chain, engaged in the research and development, production, and sales of biological reagents across three major categories: molecular, protein, and cellular. By integrating technological development pathways for molecular enzymes, proteins, antibodies, nucleic acids, and cells, Yeasen Biotechnology has become one of the few companies in China that simultaneously covers all three major categories of biological reagents, possessing both independent R&D capabilities for core technologies and large-scale production capacity.

The company develops, manufactures, and sells thousands of types of biological reagents, meeting customers’ integrated procurement needs for various categories of biological reagents. Its core product portfolio covers qPCR series, NGS series, reverse transcription series, nucleic acid extraction and purification series, PCR series, molecular cloning series, in vitro transcription series, antibodies, protein purification series, protein analysis series, recombinant proteins, cell analysis series, cell culture series, cell transfection series, reporter gene detection series, and more. These products are widely used in life science research, diagnostic testing, biopharmaceuticals, and other fields.

Shenyan Biotech, founded in 2014, is a core upstream supplier in the cell and gene therapy (CGT) sector, providing leading technical services and manufacturing tools to CGT enterprises, including viral vector production solutions and comprehensive solutions for cell therapy manufacturing.

In the realm of viral vector production solutions, Shenyan Biologics has designed and implemented its proprietary EuBioX automated laboratory system. By integrating advanced technologies such as big data analytics, bioinformatics, and automation, the company has innovatively developed the EuLV® system for the large-scale production of lentiviral vectors using stable producer cell lines. This breakthrough addresses the technical bottlenecks associated with scaling up lentiviral vector manufacturing, leveraging globally leading technology to significantly enhance production efficiency and product consistency while substantially reducing production costs.

As a leading domestic enterprise in automated cell preparation equipment, Shenyan Biology has independently developed the CellSep® series of cell processing systems, which are suitable for the standardized production of various cell-based therapies. The company has also launched sterile tube welders, heat sealers, and wave bioreactors, providing comprehensive automated solutions for cell therapy manufacturing and significantly enhancing production efficiency.

Shenyan Bio possesses unique interdisciplinary advantages and has accumulated profound technical expertise in the field of cell and gene therapy (CGT). Upholding its mission to “empower CGT and solve the industry’s most challenging problems,” the company will continue to expand the boundaries of therapeutic possibilities.

Beijing Tongli Haiyuan Biotechnology Co., Ltd. specializes in the research, development, and manufacturing of GMP-grade raw materials and reagents for cell and gene therapy (CGT), providing comprehensive product and service solutions to CGT users. Its product portfolio includes magnetic beads for cell sorting, eukaryotic/prokaryotic recombinant proteins, serum-free culture media, and cell culture kits.

The company has been honored with titles such as National High-Tech Enterprise and Beijing Specialized, Refined, Differential, and Innovative SME. It operates a 3,200 m² R&D laboratory and GMP-grade clean workshops, encompassing platforms for the development of cell sorting magnetic beads, eukaryotic and prokaryotic protein expression engineering, and serum-free culture media. The company is certified under both ISO 13485 and ISO 9001 quality management systems, and select products have obtained US FDA DMF filings.

VBPharma is a media and research platform under VCBeat that focuses on the biopharmaceutical sector. It provides innovators and entrepreneurs with communication value characterized by “depth” and “incremental growth” through two dimensions: content and operations. In terms of content, it primarily features exclusive financing announcements, corporate interviews, the “Drug Developers” column, in-depth industry analyses, and sector reports. On the operational front, its branded series “VB Think Tank” focuses on practical challenges, discusses industrial trends, and fosters tangible collaborations through the exchange of ideas.

Special Report Achievements:【CGT】【IPO-Financial Report Analysis】【iPSC】【Radiopharmaceuticals】【Protein Degraders】【Upstream Tools】【Synthetic Biology】【Organoids and Organ-on-a-Chip】【VBThinkTank] et al.